Organigram Global Inc. Q2 FY2025 Earnings Call

Good morning. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to the Organigram Global Second Quarter Fiscal 2025 Earnings Conference Call. After the speakers' remarks, there will be a question-and-answer session. Thank you. Max Schwartz, you may begin your conference.

Thank you very much, and good morning, everyone. Thanks for joining us today. As a reminder, this conference call is being recorded and the recording will be available on Organigram's website 24 hours after today's call. Listeners should be aware that today's call will include estimates and other forward-looking information from which the company's actual results could differ. Please review the cautionary language in our press release dated May 12, 2025, on various factors, assumptions, and risks that could cause our actual results to differ. Further reference will be made to certain non-IFRS measures during this call, including adjusted EBITDA, adjusted gross margin, and adjusted gross margin percentage. These measures do not have any standardized meaning under IFRS and are intended to provide additional information and, as such, should not be considered in isolation, or as a substitute, for measures of performance prepared in accordance with IFRS. Our approach to calculating these measures may differ from other issuers, so these measures may not be directly comparable. Please see today's earnings report for more information about these measures. Listeners should be aware that the company relies on reputable third-party providers in making certain statements relating to market share data. Unless otherwise indicated, all references to market data are sourced from Hifyre in combination with data from Weedcrawler, provincial boards, retailers, and our internal sales figures. Today, we'll be hearing from key members of our senior leadership team, beginning with Beena Goldenberg, Chief Executive Officer, who will provide opening remarks and commentary, followed by Greg Guyatt, Chief Financial Officer, who will review our financial results for Q2 fiscal 2025. With that, I will now introduce Beena Goldenberg, Chief Executive Officer of Organigram Global Inc. Please go ahead, Ms. Goldenberg.

Good morning, everyone, and thank you for joining us today for our Q2 fiscal 2025 earnings call. We're very pleased to report a record-breaking quarter by revenue, as well as some very encouraging operational results, which we anticipate will continue to improve as seasonal sales pick up in Q3 and Q4. This marks our first earnings call since rebranding to Organigram Global, a name that better reflects our evolution into a diversified international cannabis leader. The refreshed brand identity aligns with our position as a market leader in Canada and underscores our active expansion across Europe, Australia, and most recently, the United States. It's also the first quarter where the full impact of our Motif acquisition is reflected in our financial results. Now, let's start with a look at the Canadian market and how we're navigating the current landscape. In Q2, Canada's cannabis market grew 4% year-over-year with the strongest momentum in vapes and pre-rolls, two categories that together make up about half the market. We're especially well-positioned here. By the end of the quarter, Organigram was the #1 LP by market share in both, including a leading 21.7% share in vapes. When you add flower to the mix, these three categories, flower, vapes, and pre-rolls, represent around 85% of the total market. And we've built a strong dominant presence across all three. To put today's market structure in perspective, the top three LPs collectively hold just 27% of total market share, showing how fragmented and competitive many categories still are. But in categories like milled flower, gummies, hash, infused pre-rolls, and vapes, the top three control between 45% to 70% of the market. These are the segments where scale, production capability, and execution matter more, contributing to higher barriers and more concentration compared to flower and traditional pre-rolls. While part of our competitive edge lies in our ability to win and defend share in fragmented high-volume categories like flower and traditional pre-rolls, our strategy also includes reinforcing leadership in segments like flavor-forward milled flower, where we have over a 40% share, hash, where we have a 20% share, and gummies, where we have over 17% share. These are categories where innovation is more scalable and defensible and where we continue to outperform. Our recent entry into beverages through the Collective Project acquisition is a strong example of this dual strategy in action, entering a smaller, underpenetrated category with higher barriers to entry, where we see clear opportunity to build a dominant position as the market evolves. Collective Project beverages in Q2 represented 5.4% of the beverage market share nationally, with the majority coming from sales in Ontario. While we currently have some distribution in five other provinces, we see a path to expanding that footprint by leveraging our sales team with the goal of delivering similar sales performance as we see in Ontario. In Canada, we believe beverages have significant runway for growth. The category has matured with better tasting products and higher consumer adoption, with the category now outpacing the growth of the overall market. We're optimistic that improved products combined with potential future regulatory changes, like selling outside cannabis retail stores, could unlock the growth potential of the category. Importantly, the Collective Project acquisition also marked our entry into the US hemp-derived THC beverage market. Today, our products are distributed in 10 US states and carried by major retailers like Total Wine and Top Ten Liquors. The US market for hemp-derived THC beverages is booming, having already surpassed $1 billion in 2024 and is projected to grow to over $4 billion by 2028, according to Euromonitor International Limited. Unlike in Canada, the US regulatory framework is more flexible, allowing these products to be distributed directly to consumers or in mainstream channels like liquor, grocery, or convenience stores. When the product is available where consumers already shop, it seems that consumers are buying in. As they do, we have the product to meet their growing demand. In fact, a few days ago, Collective Project won recognition at the 2025 High Spirits Awards only a few short months following the launch of the brand in the US. We received the Gold Award for blood orange, yuzu, and vanilla, and a Platinum Award for mango, pineapple, and coconut hemp-derived THC beverages. Organigram will begin consolidating revenue from US beverage sales immediately, beginning to tap into the world's largest consumer cannabis market and setting the stage for broader international growth. Further, we plan to launch beverages with our FAST nanoemulsion technology soon, which we believe will give us a competitive edge in the category. The onset, duration, and offset for beverages with FAST is even quicker than it is in gummies, more closely resembling alcohol. On the topic of international growth, we achieved $6.1 million in international sales in Q2, a 177% increase from Q2 of last year. We anticipate the upward trend in international sales will continue as we deepen our relationships with customers abroad, particularly Sanity Group, where we've made a significant strategic investment to secure our continuous supply to the rapidly growing German market. Germany continues to represent a large growth opportunity as approximately 10% of its 80 million population self-report cannabis use, while only 0.5% are registered medical cannabis patients. Mature medical jurisdictions experience 2% to 3% registration rates. So, we believe there's still a lot of growth potential in the German medical market, notwithstanding any movement on the recreational side. Outside Germany, we continue to supply cannabis to our customers in the UK and Australia. We're also excited to share that we expect to launch branded vape products in Australia before the end of the calendar year. BOXHOT, which has grown into a $150 million retail sales brand domestically, is poised to become a meaningful player on the international stage. And we see this as an important step in expanding our branded footprint globally. Also factoring into our international growth plans is our Jupiter strategic investment pool. In February, we closed the final tranche of the $124.6 million strategic investment we've received from British American Tobacco for gross proceeds of $41.5 million. The Jupiter pool started off as an $83 million pool earmarked for international M&A and strategic investment opportunities. After our first two strategic investments in Open Book Extracts in the US and Sanity Group in Germany, Jupiter has $58 million remaining. We remain active in evaluating the best deployment opportunities for this capital, prioritizing strong ROI and increasing competitive advantages that will help accelerate growth in our international business. Now, moving on to Motif. We're making great progress integrating the Motif team, their facilities, and their operations into the broader Organigram business. All personnel are now fully under the Organigram umbrella and collaborating across both operations and administrative functions. We've been particularly impressed by the depth of expertise and talent the Motif team brings, and we're already seeing the benefits of this combined strength, such as being able to close listing gaps in our combined portfolio, thanks to a stronger, unified sales force and product lineup. Operationally, we've moved all commercial THC extraction to the Aylmer facility. That's helping us scale more efficiently and freeing up space and people in Moncton to focus on international flower. In March, we added additional shifts to Aylmer's hydrocarbon line, which now runs 24/7. With these changes, our monthly production capacity has grown significantly. We're also currently investing $800,000 in capital to further expand the extraction capacity, more than doubling our distillate production to 2,900 kilograms and our hydrocarbon isolate to 1,400 kilograms annually. The enhanced capabilities give us better cost control of our derivative inputs while increasing our B2B opportunities, helping us realize some of the key synergies of the Motif acquisition. While we're very pleased with our progress and now have a view to higher synergies than previously estimated, there's more work to be done. Some ongoing projects include the integration of our ERP system, transitioning coated pre-roll production to in-house, streamlining workflow to enhance end-to-end production efficiencies across facilities, and enhancing our London warehouse facility to allow us to distribute Moncton product through London with faster turnaround, enabling us to obtain Tier 1 status for flow-through with the OCS, as well as cut freight costs and boost on-time deliveries, which should also drive demand. All in all, we're starting to feel the momentum that this integration adds to our business, and we expect to see larger contributions and synergy realization in the back half of the year. With Collective Project, we now have another business to integrate. However, this is a much smaller asset-light business. Our focus with Collective Project is less about integrating a large operation footprint like Motif and more on expanding the distribution of Collective Project across Canada and the US. At the same time, we're pleased to share that we will begin bringing some beverage capabilities into our Winnipeg facility. Near the end of Q1, we committed to investing approximately $1.2 million into a beverage manufacturing line to leverage Winnipeg into a production hub for more of our ingestible products. While we continue to rely on co-manufacturing for beverages in Canada and the US, bringing some of our production in-house will help us scale up our beverage expertise, experiment with novel formulations, including our fast-acting soluble technology, and address incremental demand. On the topic of capital investments in Q2, we began the installation of upgraded high-intensity LED lights in half of our Moncton grow rooms, which is currently estimated to increase our flower production capacity by roughly 7,000 kilograms annually and is expected to be completed by June. This $9 million investment, before government subsidies are applied, is part of the $16 million capacity-enhancing CapEx projects we outlined in Q1 to be phased over the next 18 months and will allow us to meet the needs of a market tightening supply and increased international demand. The other $7 million project involves leveraging our London warehouse to open up space for additional grow rooms in Moncton, which is expected to increase capacity by another 7,000 kilograms annually. The London warehouse construction and licensing is expected to be completed by the end of the fiscal year. And once completed, we will relocate inventory from Moncton, freeing up space for the construction of nine additional grow rooms. This incremental Moncton capacity enhancement is expected to commence in early fiscal 2026. In addition to ensuring we can supply our increasing domestic and international flower demand, higher capacity means spreading more of our fixed costs over a larger revenue base. And speaking of flower, a quick update on seed-based production. This is an enterprise-level innovation, which we are pioneering on a large scale to modernize cannabis production and bring it to the same level as other mature agricultural industries. Seed-based harvest from F1 stabilized seeds are robust, uniform, with specific characteristics, which together result in more consistent and repeatable flower. Given the demand for consistency and quality, both at home and abroad, this lower cost and faster alternative to clone-based production has the potential to transform the way cannabis is cultivated at scale. In Q2, 22% of our harvest came from seed-based production. We continue to work with our strategic investee, Phylos Bioscience, in the US to step up our efforts to stabilize strategic genetics while we continue genomics research to identify genetic markers that influence things like resistance to powdery mildew, terpene expression, THC potency, yield, and more. Looking at where we are now and where we want to go, we have a few key areas of focus in the coming quarter: One, we will focus on accelerating international revenue growth by capitalizing on increased export volume, initiating branded international sales in the US and Australia, and leveraging our forthcoming EU-GMP certification. Two, we will look to gain market share in Canada, leveraging consumer-centric innovations in the fastest-growing categories like BOXHOT Diamond Doobies, SHRED Heavy Slims, Debunk Liquid Diamond vapes, and ongoing growth in Big Bag O' Buds. Three, we will increase gross margins and deliver consistent cash flow from operating activities through Motif synergies, higher scale and capacity, growth in international, and controlling costs. And four, as the market leader in Canada, we will continue to strongly advocate to key government officials through our enhanced government relations program, focusing not only on changes that will support our business, but the sector as a whole. Our goal is to build consensus at the federal, provincial, and territorial level for the need for common sense cannabis regulations, excise reform, and a national export strategy that defends an industry that contributes more to the Canadian GDP than breweries or wineries and distilleries. On that note, I will turn it over to Greg to discuss our financial performance for the quarter.

Thank you, Beena. We are very pleased to report a record quarter ahead of key seasonality in Q3 and Q4 as we believe our results will continue to improve throughout the year in line with previous guidance. We experienced strong year-over-year growth in the quarter. Our gross sales were up 79% and surpassed $100 million for the first time in any given quarter. Similarly, our net revenue was up 74% year-over-year to reach $65.6 million. These results were supported by a full quarter of financial contributions from our Motif business as well as organic growth in our recreational and international businesses. As we scale both domestic and international sales, fueled by growth in Germany, the launch of branded sales in the US and the expected launch of branded sales in Australia this fiscal year, we are beginning to approach the milestone of becoming a $0.5 billion run rate business by ship sales. In Q2, our international sales increased 177% to $6.1 million from $2.2 million in the same prior-year period and increased 84% sequentially since last quarter from $3.3 million. Building off of our leadership in Canada, we are aggressively pursuing growth in international markets through strategic acquisitions in growth markets, and we continue evaluating a robust pipeline of strategic opportunities supported by our Jupiter pool of approximately $58 million. Adjusted gross margin for the quarter increased to $21.9 million or 33%, compared to $11.6 million or 31% in the same prior-year period. This improvement was primarily driven by growth in our recreational business following the Motif acquisition, as well as increased contributions from international sales. On a sequential basis, adjusted gross margin remained flat. While we benefited from greater scale and stronger international shipments, Motif margins were lower than the core Organigram business, which reduced our overall adjusted gross margin. Organigram's standalone adjusted gross margin was 37% in the quarter. We expect Motif margins will benefit from the realization of integration synergies, which will build throughout the back half of the year to $5 million this year, partially driven by recent capital expenditures designed to improve operational efficiency and capacity at Motif. As a result of the work done so far, we are now expecting our annual synergies to reach approximately $15 million next year, up from the previously disclosed $10 million. Although these offsetting factors resulted in a flat adjusted gross margin in the quarter, we exited March with an adjusted gross margin of over 39%. As noted in previous quarters, we continue to expect adjusted gross margin to stabilize around 35% for fiscal 2025, with stronger performance anticipated in Q3 and Q4 with our long-term adjusted gross margin target of 40% in the second half of fiscal 2026. G&A costs in the quarter were flat at $14.9 million compared to Q2 of last year, including the incremental costs from Motif. This is reflective of controlling overhead and new business integration. Included in our G&A cost were ERP expenditures of approximately $0.6 million for the final phase of our ERP project, which is expected to be completed by the end of this year. Selling costs for the quarter, including marketing, were $7.5 million versus $5.4 million last year. The increase was attributed to higher trade investments with retail partners to support the growth of the business. Total SG&A costs for the quarter were $22.4 million, a modest increase of 10% versus the prior period last year. As a percentage of net revenue, SG&A was 34%, down from 54% last year and 40% last quarter. Adjusted EBITDA for the quarter was $4.9 million compared to negative $1 million in the prior-year period. The year-over-year increase was primarily due to higher gross margin as a result of higher international sales and increased operating efficiency and scale. With $6.3 million in adjusted EBITDA for the first six months and seasonally stronger quarters to come, we are on track to outperform fiscal 2024 adjusted EBITDA this fiscal year. Net income for the quarter was $42.5 million compared to a net loss of $27.1 million in Q2 fiscal 2024. The largest contributing factor here was the change in the fair value of derivative liabilities, of which just over $35 million was associated with BAT's top-up rights and the issuance of preferred shares associated with the final $41.5 million tranche from BAT. On a smaller scale, we saw some additional non-cash benefit from the appreciation of our investments in Phylos, OBX, and Sanity Group. From a cash flow perspective, cash used by operating activities before working capital changes was $1.6 million in the quarter compared to cash used of $8.3 million in the prior-year period. The change in cash used was primarily due to improvements in adjusted gross margin versus the prior year. On the topic of cash, we maintain a strong balance sheet and remain confident in our liquidity position, which we believe is sufficient to fund operations and strategic growth initiatives following recent acquisitions while supporting our near- to mid-term goal of consistent profitability. As of March 31, we had a total cash position of $83.4 million, including both restricted and unrestricted cash and negligible debt. We plan on investing $8 million to $10 million in sustaining capital expenditures during fiscal 2025. As Beena mentioned, we've started to invest in the previously mentioned Moncton flower capacity enhancement project. These capital expenditures will be funded out of operating cash flow and we will continue to evaluate our long-term cash needs and optimize our capital structure accordingly. We are encouraged by our performance this quarter as our continued focus on efficiency, scale, and market leadership alongside the acceleration of our international strategy translates into meaningful year-over-year growth. As we move through fiscal 2025, we expect to reduce costs as a percentage of net revenue while increasing the mix of higher margin international sales. At the same time, we're seeing tightening supply in the Canadian market, which presents an opportunity to expand flower capacity and take price on our category-leading brands. We look forward to updating you on our progress in the quarters ahead. With that, I will turn the call back to Beena.

Thank you, Greg. As we progress through fiscal 2025, we are confident in our ability to execute on our strategic priorities. The integration of Motif, revenue expansion on Collective Project, our international expansion efforts, and the continued success of our innovation pipeline, all position us well for sustained growth and improved profitability. We appreciate the continued support of our shareholders, customers, and employees. We remain committed to driving innovation, operational excellence, and long-term value creation. Now, let's open up the floor for questions.

Thank you. We will now begin the question-and-answer session. Your first question comes from Aaron Grey with Alliance Global Partners. Please go ahead.

Good morning. Thank you very much for the questions. So, first question for me, you guys talked a lot about international, some of your growth aspirations. So, if we could just dive a little bit deeper into your outlook for 2025 and fiscal. I know EU-GMP certificate doesn't change capacity and you're already selling into markets, but given the greater margin capture you'll have with the EU-GMP change, how do you think about allocating capacity internationally, given the greater margins you'll get there versus balancing the Canadian market share aspirations that you have? So, any color on any capacity constraints you might have, how you're looking to balance between your goals domestically and internationally? Thank you.

Yes, thanks for the question, Aaron. We will continue to balance the demands of both domestic and international sales. While international sales have higher margins due to the absence of excise taxes, we want to maintain our strong position in domestic flower brands like Big Bag O' Buds, which are still growing well. This balance is crucial, especially since some competitors have decided to exit the domestic market. We anticipate more price pressures in international markets, as we're already seeing value flower appearing in Germany, with supply coming from various global sources, not just Canada. To ensure a long-term strategy, we need to strike this balance. We are seeing increased demand from some international markets, which is why we're focusing on expanding our flower capacity. We've made improvements to our facility's efficiency, with 7,000 kgs coming from our LED upgrade already showing benefits as the project nears completion, and rooms that resumed production a couple of months ago are now generating additional flowers. Together, these projects will add 14,000 kilos of capacity while we continue to enhance our flower efficiencies. We expect to see increased international sales in the second half compared to the first half. Additionally, for international sales, we need to engage medical doctors to prescribe specific cultivars, which are gaining traction in Germany and are expected to lead to higher demand. We're excited about this opportunity, but it will require careful balancing. Although we appreciate the margins that come with international sales, domestic market margins are improving due to reduced competition, allowing us to increase pricing there.

Really appreciate that color there, Beena. That was helpful. Second question for me. I just want to talk a little bit about the margin evolution. You gave some great color there on the gross margin. So, as we think about EBITDA profitability, where do you believe EBITDA margins have the potential to get to in the medium term? And what are some of the most meaningful levers? You gave some color in terms of incremental synergies that you found going from $10 million to $15 million. Was that more so on the gross margin side or on the SG&A side? And then, how much of those synergies have been realized today? So, any color in terms of the margins, how we should think about the evolution will be helpful. Thanks.

Sure. Thank you for your question. First, I'll discuss the synergies. We have realized approximately $1.5 million of the $5 million target for this year. Most of this is related to cost of goods sold, but we have also seen some overhead savings from cost avoidance and the overall integration of the two businesses. Looking ahead, the growth in EBITDA will stem from a combination of margin expansion and effective cost management. We are aiming for around a 40% gross margin in the latter half of fiscal 2026. Additionally, we are focused on controlling expenses, which means we do not anticipate significant growth in SG&A as revenue increases. This is crucial as we begin to scale our top line, allowing for better leverage on the profit and loss statement, which will positively impact EBITDA. In the long term, we expect EBITDA to grow as a percentage of sales. As we approach the stronger seasonal periods of our business later in the year, we expect to see an improvement in the EBITDA margin as well.

Okay. Great. Really appreciate that color. I'll go ahead and jump back into the queue.

Your next question comes from the line of Frederico Gomes with ATB Capital Markets. Please go ahead.

Hi, good morning. Thanks for taking my questions. First question is on the cash flow. We saw negative cash flow this quarter. I think a good portion of that was related to working capital. So, first, could you maybe talk about the drivers behind those working capital changes this quarter, maybe the key items here that drove that? And second, could you talk about your cash flow expectations for the remainder of the year, things like movements in working capital, CapEx, as well as the potential margin expansion and the seasonality that you mentioned as well? Thanks.

Sure. Maybe I'll start with the cash question. Thanks, Frederico. So, in Q2, we actually spent $6 million at the end of the quarter on the Collective Project acquisition. So, that had a negative impact on cash flow just from a timing perspective. But primarily, the biggest driver, as you mentioned, was our investment in working capital, which was very intentional. Q3 and Q4 is really our strongest time of the year. So, in Q2, our plan was to invest in working capital to ensure that we're prepared for the strong growth that's to come. Now, with working capital, there's a number of puts and takes, but the most significant increase was an increase in inventory, which is required to be prepared for the growth that's coming for the next two quarters. Did I cover everything, Frederico?

Yeah. Maybe just the second part of the question, related to your expectations for the remainder of the year. I guess, you answered sort of the question about the working capital for the second half, but also CapEx and the impact of the potential margin expansion.

From a CapEx perspective, we're expecting to spend on regular sustaining capital, $8 million to $10 million for the full year, as well as the $9 million that was mentioned for the Moncton LED grow room expansion. The timing of that, we expect most of it to happen this year. And so, you'll see that being funded through operations, which as we mentioned, Q3 and Q4 is going to be our strongest period for the year of cash flow. So, we actually expect to be cash flow positive for the full year and we'll see that starting to come through in the third quarter.

Perfect. I appreciate that, Greg. And then, maybe just a second question for me. If you could comment on your strategy for the US hemp-derived THC market. I know that you talked a little bit about that. We know there's a lot of brands in the marketplace today. A lot of other companies investing in that market as well. So, how do you plan to differentiate? And in regards to margins in that segment, when do you think they could be accretive and they could be meaningful to your overall margins? Thank you.

Sure. So, let's start off by saying, listen, we're early days in expanding the Collective Project brand in the US market, and we're very excited about the results so far in the markets where it's on the store shelves. We're talking to retailers, and the offtake is strong. It is our intention to continue to build out the distribution. Right now, we're selling into 10 provinces. We expect to see stronger distribution probably in another six provinces before the end of the fiscal year. And we expect our direct-to-consumer website to start to launch this month. So, continuing to build that way. The priority right now in the US is to drive trial and awareness. We have a very strong summer support program kicked off to drive velocity at retail, so offtake, really get to consumers. What we think is the benefit of Collective Project, and you're right, there are many brands in the US, but some of them are not very good. They don't taste very good. We have great-tasting products with Collective Project. As I mentioned, the awards we just received and we're excited about getting people to try. So, we have a lot of sampling programs during the summer. In places where you can't have infused samples, we'll have non-infused samples. We'll have a lot of POS and programs. So, back to your question about margins in the short term, we're investing to drive the growth of this product. So, we expect to do roughly $1 million in US retail sales. So, it's still small, but we're investing that margin back to drive the offtake and to increase awareness. This is a key part of our strategy in the US. Obviously, in Canada, we expect to see growth in our business and that will grow and appreciate the gross margin that comes with that business.

Thank you very much, Beena.

Your next question comes from the line of Yewon Kang with Canaccord Genuity. Please go ahead.

Hi, good morning. Thank you for taking my question. Apologies if I missed some of the remarks in the opening statements, but the international sales saw a significant sequential increase. So, just wondering if you could provide some color on what drove that growth. Was it primarily due to the expanded orders from existing partners like the Sanity Group, or did you onboard new customers during the period? Thank you so much.

Certainly. The growth we saw was not from new customers but from meeting the increased demand of our existing customers, including some strong partners in Australia. There is a consistent demand for high-quality products. While there's a lot of talk about international flower from places like Colombia or South Africa, we have been growing high-quality cannabis for some time, and it is recognized globally. As medical markets develop, once a specific cultivar gains traction through prescriptions, consumers tend to return to that cultivar. Initially, the demand may be modest, but it builds over time through repeat purchases. When entering international markets, it's crucial to have stability data for the cultivars, as building demand takes time, but once established, it leads to increasing orders, which we are beginning to witness. We're anticipating our EU-GMP certification soon, which won't boost demand but will enhance our fulfillment speed by eliminating intermediaries. This means faster market delivery and quicker repeat orders. We are also looking forward to the potential for increased pricing with EU-GMP certification due to the removal of those middlemen. Our international business is poised for growth, but again, it's driven by significant demand from our current customers, which we prioritize fulfilling.

Thanks for that color. Just the second one from me here is on the Collective Project acquisition. It's been a few weeks and, obviously, very early days since integrating that brand into your platform, but I was wondering if you guys could provide any color into any insight that you might have gained from having exposure into the US hemp-derived space. Any differences between how the recreational market functions even on the consumer level and any insights there would be helpful. Thank you.

Certainly. We completed the Collective Project on March 31, marking the end of the quarter. It's still early in the process, but I can share a few details about the Collective Project. In Canada, we have strong partnerships with our co-manufacturers. As the licensed producer, we are transitioning those relationships since the Collective Arts team is not a licensed producer. This will allow us to gain efficiencies in production and distribution while leveraging our sales team for increased distribution. We also have connections with the Boards that can help facilitate this. We're optimistic about the revenue growth potential in Canada. Additionally, we've invested $1.2 million in our Winnipeg facility, where we are developing new formulations and integrating our FAST nanotechnology to further differentiate our products. Bringing more production in-house will allow us to better utilize our infrastructure and enhance our margins. In the US, the situation is a bit different as we rely on co-man relationships. We have recently switched our co-manufacturer for the Collective Project, which has led to improved costs and quality of the final product. We maintain solid relationships with key distributors to expand our market presence and establish connections with important retailers. Our primary focus for the Collective Project in the US is on distribution and increasing brand awareness to encourage trial usage. There are only four major players in the US that offer hemp-derived THC beverages with significant financial backing to drive trials, and we are excited to be one of them. Our goal is to continue growing in the US market.

Thank you for the color. I'll hop back into the queue.

Thank you.

And we have no further questions in our queue at this time. I will now turn the conference back over to management for closing comments.

Well, thank you everybody for joining our call today and thanks for your insightful questions. We are really looking forward to our key seasonality coming up in Q3 and Q4, looking forward to seeing the expansion of our Collective Project acquisition, the realization of the Motif synergies, the growth in our international sales, and we look forward to updating you further next quarter. Thanks, and have a good day.

Ladies and gentlemen, this does conclude today's conference call. Thank you for your participation, and you may now disconnect.